rs1799963 — F2 G20210A

The Prothrombin G20210A Variant — A Hidden Clotting Accelerator

Prothrombin — also called coagulation Factor II — is the precursor to thrombin, the central enzyme that converts fibrinogen into fibrin clot. The G20210A mutation in the prothrombin gene (F2) doesn't change the structure of prothrombin itself; instead, it quietly turns up its production. Carriers make 30% more prothrombin¹¹ 30% more prothrombin
Plasma prothrombin levels measured in multiple studies; homozygotes produce roughly 70% above baseline than the average person, and that excess shifts the coagulation balance toward clotting. This makes G20210A the second most common inherited thrombophilia²² second most common inherited thrombophilia
After Factor V Leiden, which affects approximately 5% of Europeans; G20210A affects 1-3% in people of European descent, with a carrier frequency of 1-3% in this population.

The Mechanism

The G20210A variant sits at position 20210 in the 3' untranslated region (3' UTR)³³ 3' untranslated region (3' UTR)
The non-coding tail of mRNA that controls stability, export, and how efficiently the message is translated into protein of the F2 gene on chromosome 11. This is the final nucleotide before the polyadenylation signal — the molecular "stop" marker that terminates mRNA. Replacing guanine with adenine at this position creates a more efficient cleavage site for the RNA processing machinery. The result is enhanced 3' end processing, more stable mRNA, and greater protein output⁴⁴ enhanced 3' end processing, more stable mRNA, and greater protein output
Functional studies by Gehring et al. confirmed enhanced polyadenylation efficiency is the core mechanism. Prothrombin plasma levels rise 30% in heterozygotes and approximately 70% in the rare homozygotes.

More prothrombin in circulation means more thrombin available whenever coagulation is triggered, lowering the threshold for clot formation without directly disrupting the normal regulatory mechanisms. The coagulation system becomes hair-triggered — adequate for normal hemostasis but prone to excessive clotting under provocation (surgery, immobility, hormonal changes, pregnancy).

The Evidence

The variant was first described in 1996 by Poort and colleagues⁵⁵ first described in 1996 by Poort and colleagues
Seminal paper in Blood identifying G20210A in 28% of families with unexplained venous thrombosis. The original cohort showed a 2.8-fold increased risk of VTE in heterozygous carriers, and this estimate has held up across decades of replication.

A pooled analysis of 8 case-control studies⁶⁶ pooled analysis of 8 case-control studies
2,310 VTE cases and 3,204 controls; Study Group for Pooled-Analysis in Venous Thromboembolism established that the interaction with Factor V Leiden is clinically critical: double heterozygotes — carrying both G20210A and the Factor V Leiden mutation (rs6025) — face an odds ratio of 20 for venous thromboembolism, versus 3.8 for G20210A alone. A more recent FinnGen and UK Biobank analysis of 26,000+ carriers⁷⁷ FinnGen and UK Biobank analysis of 26,000+ carriers
Published in Blood 2024 estimated the double-heterozygote OR at 5.24, suggesting the classical 20-fold estimate from smaller studies was inflated — but even the conservative biobank estimate represents an enormous absolute risk elevation.

The interaction with combined oral contraceptives (estrogen-containing pills)⁸⁸ combined oral contraceptives (estrogen-containing pills)
OC use independently increases VTE risk 3-5 fold through increased coagulation factor production and reduced fibrinolysis is particularly clinically important. Women carrying G20210A who use combined oral contraceptives face an estimated 6- to 16-fold elevated VTE risk compared to non-carriers not using OCs. Progestin-only pills and non-hormonal methods (copper IUD, levonorgestrel IUD) do not carry this additional risk.

For recurrent VTE risk⁹⁹ recurrent VTE risk
Meta-analysis of prospective studies through 2024, heterozygous carriers who have already experienced one VTE event face a 79% increased risk of recurrence compared to non-carriers.

Practical Implications

The actionable implications of this variant fall into three categories. First, women of reproductive age should discuss contraception choices with their physician — estrogen-containing methods carry elevated risk that is specific and avoidable. Second, any known carrier facing elective surgery, prolonged immobility (long-haul flights, hospitalization), or major hormonal changes (pregnancy, postpartum) should have this documented in their medical record and discuss thromboprophylaxis with their doctor. Third, first-degree relatives of a carrier have a 50% chance of carrying the same variant and may benefit from testing, especially before events that trigger thrombosis.

Anticoagulation after a first VTE event is managed the same way regardless of G20210A carrier status — typically 3-6 months of anticoagulation for provoked events, longer for unprovoked. The G20210A status is most relevant for the recurrence risk discussion and whether extended anticoagulation is warranted.

Interactions

The most clinically important interaction is with Factor V Leiden (rs6025, F5 R506Q)¹⁰¹⁰ Factor V Leiden (rs6025, F5 R506Q)
Factor V Leiden is the most common inherited thrombophilia, present in 5% of Europeans; double heterozygosity compounds risk multiplicatively. A person carrying both G20210A and Factor V Leiden has coagulation hyperactivated at two independent checkpoints simultaneously, producing far greater risk than either variant alone. This double heterozygous combination should be flagged as a high-priority compound interaction.

Acquired thrombophilic states — antiphospholipid syndrome, cancer, nephrotic syndrome, polycythemia vera — compound with inherited thrombophilias including G20210A in an additive or synergistic manner. The number of 20210A alleles carried (0, 1, or 2) also matters: homozygotes face substantially higher risk than heterozygotes, though homozygosity is rare (approximately 0.01% of Europeans).